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Abstract
Objectives: The effects of AT1 receptor blocker, telmisartan, and the ACE inhibitor, ramipril, were tested head-to head and
in combination on stroke prevention in hypertensive rats and on potential neuroprotection in acute cerebral ischemia in
normotensive rats.
Methods: Prevention study: Stroke-prone spontaneously hypertensive rats (SHR-SP) were subjected to high salt and
randomly assigned to 4 groups: (1) untreated (NaCl, n=24), (2) telmisartan (T; n=27), (3) ramipril (R; n=27) and (4)
telmisartan +ramipril (T+R; n=26). Drug doses were selected to keep blood pressure (BP) at 150 mmHg in all groups.
Neurological signs and stroke incidence at 50% mortality of untreated SHR-SP were investigated. Intervention study:
Normotensive Wistar rats were treated s.c. 5 days prior to middle cerebral artery occlusion (MCAO) for 90 min with
reperfusion. Groups (n=10 each): (1) sham, (2) vehicle (V; 0,9% NaCl), (3) T (0,5 mg/kg once daily), (4) R (0,01 mg/kg twice
daily), (5) R (0,1 mg/kg twice daily) or (6) T (0,5 mg/kg once daily) plus R (0,01 mg/kg twice daily). Twenty-four and 48 h
after MCAO, neurological outcome (NO) was determined. Forty-eight h after MCAO, infarct volume by MRI, neuronal
survival, inflammation factors and neurotrophin receptor (TrkB) were analysed.
Results: Stroke incidence was reduced, survival was prolonged and neurological outcome was improved in all treated SHR-
SP with no differences between treated groups. In the acute intervention study, T and T+R, but not R alone, improved NO,
reduced infarct volume, inflammation (TNFa), and induced TrkB receptor and neuronal survival in comparison to V.
Conclusions: T, R or T+R had similar beneficial effects on stroke incidence and NO in hypertensive rats, confirming BP
reduction as determinant factor in stroke prevention. In contrast, T and T+R provided superior neuroprotection in
comparison to R alone in normotensive rats with induced cerebral ischemia.
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Introduction
Several recent clinical trials have demonstrated the efficacy of
angiotensin AT1 receptor blockers (ARBs) and angiotensin-
converting enzyme inhibitors (ACEI) in primary and secondary
prevention of stroke in patients with hypertension and/or high
cardiovascular risk [1–6]. Whereas the antihypertensive actions
of these drugs are thought to contribute to their stroke-
preventing features, the question as to potential blood
pressure-independent neuroprotective effects of renin-angioten-
sin-system (RAS) inhibitors under cerebral ischemia still remains
open, especially since clinical drug trials on stroke, for obvious
reasons, usually address stroke incidence alone and rarely issues
of neuroprotection.
ACE inhibitors and angiotensin receptor antagonists both target
the RAS, though in different ways. ACE inhibitors never block the
RAS completely. Even when ACE is inhibited by more than 90%,
there will still be some angiotensin II production by other enzymes
that compensate for the lack of ACE activity. Angiotensin receptor
antagonists, on the other hand, feature a more specific mechanism
since they selectively block the angiotensin receptor subtype-1
(AT1), which is responsible for most of the deleterious effects of
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subtype-2 (AT2) to increased angiotensin II concentrations.
Published data suggest that the AT2 receptor can counterbalance
the effect of the AT1 receptor in vitro as well as in vivo [7]. It has also
been speculated that combining ACE inhibition and AT1 receptor
blockade could have advantages over each therapeutic principle
alone [8] but with respect to neuroprotection in cerebral ischemia,
this hypothesis has not yet been tested.
In the present study, we addressed two questions: First, in a well
established hypertensive animal model with cerebrovascular
disease and a high incidence of stroke, the salt-fed stroke-prone
spontaneously hypertensive rat (SHR-SP), we asked whether a
similar inhibition of the RAS as evidenced by equal blood pressure
reductions by ACE-inhibition, AT1 receptor blockade, or their
combination would engender comparable effects on stroke
incidence and stroke-related morbidity and mortality (prevention
study).
Second, in normotensive rats, we evaluated the potential blood
pressure-independent neuroprotective effects and mechanisms of
subantihypertensive treatment regimens involving comparable
blockade of ACE or AT1 receptors or combined treatment with
both of these principles (acute intervention study).
We used telmisartan as ARB and ramipril as ACEI since these
drugs have recently been used alone and in combination in a large
clinical trial involving stroke prevention in patients with high
cardiovascular risk [6]. In the rat, both drugs have been
demonstrated to cross the blood-brain barrier with telmisartan
having a higher propensity to enter the brain than ramipril [9,10].
Materials and Methods
Animals and treatment
Rats were kept in a SPF (specific pathogen free) barrier under
standardized conditions with respect to temperature and humidity,
and were housed on a 12 h light/12 h dark cycle in groups of 4–5
with food and water ad libitum. Animal housing, care, and
applications of experimental procedures were approved by State
Office of Health and Social Affairs Berlin, Germany (project IDs
G0034/06 and G0088/04).
The human end point was set by a neurological score of 3.
Prevention study
Male SHR-SP (n=104), aged 7 weeks, were obtained from
Charles River Laboratories (Sulzfeld, Germany). Baseline mea-
surements (MRI, blood pressure by tail cuff method) and
neurological score were performed at the age of 9 weeks.
Subsequently, all rats were switched to a high salt diet (RMH-
TM rat chow; protein 22.5%; fat 4.8%; potassium 0.85%; sodium
0.40%; Hope Farms, Sniff, Soest, Germany) and 1% NaCl
(170 mmol/L) in the drinking water in order to accelerate the
appearance of cerebrovascular events [11]. With the beginning of
the high salt diet, SHR-SP were randomly assigned to four
different treatment groups: group 1 served as control (untreated;
n=24), group 2 treated with the angiotensin AT1 receptor blocker
telmisartan in the drinking water (initial dose T; 1.23 mg/kg bwt;
n=27), group 3 treated with the ACE-inhibitor ramipril in
drinking water (initial dose R; 1.06 mg/kg bwt; n=27), and group
4 was treated with a combination of telmisartan and ramipril in
the drinking water (initial dose T; 0.25 mg/kg bwt plus R,
0.25 mg/kg bwt; n=26) (Figure S1A). Individual drug doses were
selected on the basis of achieving equal blood pressure
(150 mmHg) throughout the protocol (Figure 1A).
Systolic blood pressure was measured weekly in trained,
conscious and pre-warmed rats by tail cuff method using a model
from ADInstruments with PowerLab software [12]. Rats were
screened daily for neurological disorders by the scoring system of
Garcia et al. [13]. The protocol was terminated at 50% mortality
in the untreated SHR-SP group (Figure 1A–D).
Acute intervention study
In a pilot study, male normotensive Wistar rats (160–200 g,
HARLAN Winkelmann, Borchen, Germany) were randomly
divided in several groups (Ang I+0,9% NaCl; Ang I+R
0.01 mg/kg; Ang I+T 0.05+R 0.01; Ang II+0,9% NaCl; Ang
II+T 0.05 mg/kg, Ang II T 0.05+R 0.01; n: 5 per group) to
determine the appropriate treatment doses of the comparators
(Figure 2A–B; Figure S2A–B).
Based on the above dose finding, further animals were
randomly allocated to five different treatment groups (n=10
each): (1) sham-operated, vehicle (V; 0.9% NaCl once daily)
treated, (2) stroke V (0.9% NaCl once daily) treated, (3) stroke T
(0.5 mg/kg once daily) treated, (4) stroke R (0.01 mg/kg twice
daily) treated, (5) stroke R (0.1 mg/kg twice daily) treated or (6)
stroke T (0.5 mg/kg once daily) plus R (0.01 mg/kg twice daily).
Subcutaneous (s.c.) drug treatment was begun 5-days prior to
MCAO [14] (Figure S1B).
Femoral artery and vein catheter in acute intervention
study
Two days before blood pressure recordings (pilot study) and
three days after initiation of treatment (main study), polyethylene
catheters (PP-50) were inserted through the femoral artery into the
abdominal aorta and in the femoral vein. The arterial catheter was
used for blood pressure measurement via a transducer using the
software PowerLab by ADInstruments (Spechtbach, Germany).
The femoral vein catheter was used for intravenous (i.v.) injections
of angiotensin II (Ang II; 50 ng/kg bwt) and angiotensin I (Ang I;
150 ng/kg bwt), respectively [15].
Determination of equipotent doses of telmisartan,
ramipril and their combination in vivo for acute
intervention study
On day two after catheterization, five animals per group were
placed into individual cages and connected via the arterial catheter
to a transducer for hemodynamic measurements and, via the
venous line, to a microsyringe for small volume injections. After
baseline blood pressure recordings for 30 min, animals received an
intravenous (i.v.) bolus injection of Ang II or Ang I, respectively.
Rats were then treated s.c. with NaCl solution, telmisartan or
ramipril or their combination at different doses. The pressor
responses to i.v. bolus injections of Ang II (telmisartan group or
combination group) or Ang I (ramipril group or combination
group) were recorded at time intervals of 5, 15, 30, 60 and 90 min
and 3, 6 and 10 hours after s.c. vehicle, telmisartan or ramipril or
their combination.
Bolus i.v. injections of Ang II or Ang I, five, 15, 30, 60 and
90 min after s.c. treatment with vehicle elicited consistent
increases in mean arterial pressure of about 40 mmHg. Subcuta-
neous injection of telmisartan prior to Ang II dose- and time-
dependently attenuated the pressor responses to the peptide. At
0.1 mg/kg bwt, telmisartan was not effective, whereas at 0.5 mg/
kg bwt, telmisartan completely inhibited the pressor responses to
Ang II within 30 minutes of s.c. administration. Based on these
findings, a telmisartan dose of 0.5 mg/kg bwt was determined to
be used in further experiments (Figure S2A).
The corresponding dose of ramipril, established by the same
criteria as above (with exception that Ang I instead of Ang II was
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blocked the pressor responses to i.v. Ang I by 90–100% from 30 to
90 min (Figure S2B).
The inhibition of the respective Ang II- and Ang I pressor
responses with the above doses of telmisartan and ramipril after 3,
6 and 10 hours are shown in Figure 2A. Both compounds were
inhibitory for 10 hours. Thereafter, ramipril lost effectiveness
faster than telmisartan (Figure 2B). Based on these findings, a
treatment protocol with twice daily s.c. injections was established
for ramipril to guarantee continuous 24–hour RAS blockade
in vivo.
Since inhibition of the brain RAS inside the blood-brain barrier
(BBB) has been demonstrated to be neuroprotective under
ischemic conditions [14–18] and since peripherally administered
ramipril, at the dose established above, may penetrate the BBB less
readily than telmisartan [9,10], we introduced an additional group
of rats pre-treated s.c. with ramipril at 0.2 mg/kg bwt (ramipril
high dose) to allow for better comparison between drugs.
Figure 1. Prevention study SHR-SP. A) Development of systolic blood pressure in hypertensive treated and untreated rats measured by tail cuff
method. Results area expressed as mean SEM. *p,0.05 or **p,0.01 significant differences between treatment groups and vehicle. B) Effect of vehicle,
telmisartan, ramipril or telmisartan plus ramipril supplemented in drinking water on neurological deficits in salt-loaded, stroke-prone spontaneously
hypertensive rats. *p,0.05 telmisartan treated group; **P,0.01 ramipril treated group vs vehicle group, 13 weeks of age.
#p,0.01 telmisartan,
ramipril and telmisartan + ramipril treated groups vs vehicle group, 14–20 weeks of age.
##p,0.05 telmisartan + ramipril treated group;
$p,0.01
telmisartan, ramipril treated groups vs vehicle group, 21 weeks of age. C) Survival rate in salt-loaded, stroke prone spontaneously hypertensive rats
(SHR-SP). Nine week-old SHR-SP were treated with vehicle, telmisartan, ramipril or telmisartan plus ramipril supplemented in drinking water. Figures
under the curve show number of surviving animals. Mortality was compared among groups using Kaplan Meier analysis of survival followed by log-
rank test. *p,0.001; telmisartan, ramipril and telmisartan + ramipril treated groups vs vehicle group. D) Representative picture of SHR-SP with vehicle
and stroke and with treatment without stroke.
doi:10.1371/journal.pone.0023646.g001
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Five days after the beginning of treatment, focal cerebral
ischemia was induced by right middle cerebral artery occlusion
(MCAO) with subsequent reperfusion as described previously
[16,19]. Under general anaesthesia with chloralhydrate 400 mg/
kg, the right cervical carotid bifurcation was exposed through a
midline neck incision. A 4–0 silicon-coated nylon monofilament
(Prolene, Ethicon GmbH, Norderstedt, Germany) was gently
inserted through the proximal external carotid artery (ECA) into
the internal carotid artery up to middle cerebral artery offshoot.
After 90 minutes, the filament was withdrawn into the stump of
the ECA to allow reperfusion (Figure S3A). Sham-operated rats
underwent the same surgical procedures except that the occluding
monofilament was not inserted. Cerebral blood flow (CBF) was
monitored during surgical intervention with a probe attached to
the skull above the supply territory of the MCA (2 mm caudal to
bregma, 6 mm lateral to midline) by Laser-Doppler flowmetry
(Periflux system 5000, PERIMED, Stockholm, Sweden). The
procedure was considered successful, when an over 75% drop in
CBF was observed after MCAO (Figure S3B). BP was measured
before, during and after MCAO with atrial catheter (Figure 3A).
Body weight was investigated before and after surgery (Figure 3B).
T2-weighted Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) was performed 48 hours
after MCAO on a 7 T Bruker scanner (Pharmascan 70/16 AS,
Bruker Biospin, Ettlingen, Germany) in isoflurane anaesthesia.
Cerebral ischemic areas were visualized with a T2-weighted; fat
suppressed 2D turbo spin-echo sequence (TR 5218.7 ms; TEeff
65.2 ms, RARE factor 8 and 6 averages). 35 axial slices with a slice
thickness of 0.5 mm and no interslice distance were positioned to
cover the whole brain. The field of view (FOV) was 3.563.5 cm
and the matrix was 2566256 resulting in an inplane resolution of
137 mm. Calculation of lesion volume was carried out with the
program Analyze 5.0 (Analyze Direct, Inc.; Lenexa USA) [13,19]
(Figure 3 C).
Neurological score
Neurological evaluation was accomplished by a blinded
observer 24 h and 48 h after MCAO using the 18-point
neurological scoring system of Garcia et al [13,20]. This
neurological score will test for spontaneous activity, motor
impairments and sensorial function. Severe impairments were
graded 0 or 1, and no observed deficits were graded 3 (Figure 3D).
Blood parameters
Blood samples were taken by retrobulbar puncture to determine
oxygen- and carbon dioxide-partial pressure, pH, hematocrit,
glucose-, sodium- and potassium concentration before and after
MCAO (Table S1). Data were quantified using a RADIOMETER
ABL 555 SERIES (Radiometer medical A/S, Copenhagen,
Denmark).
Nissl staining
Rat brains were coronally sectioned into slices of 7 mm thickness
in a cryostat and, subsequently, fixed in acetone for 5 min. For the
staining of viable neurons sections were incubated with Neuro-
Trace (diluted 1:50 in PBS) followed by DAPI staining (both from
Molecular Probes, Eugene, Oregon, USA) according to the
manufacturer’s instructions. The area for counting the positively
stained neurons was determined by comparing HE-stained
sections and MRI sections of the animals of the experiment to
choose an area of approx. 1 mm
2 in the periventricular penumbra
in all animals. In addition, the corresponding area in the
contralateral hemisphere was investigated. Cells were counted by
a blinded investigator (Figure 4A).
Immunofluorescent staining
For staining of intracellular cytokines TNFa and IL-6, sections
were blocked with 5% donkey serum (PAN Biotech GmbH,
Aidenbach, Germany) and with 10% donkey serum for staining of
TrkB, both diluted in PBS. Subsequently, the blocking buffer was
removed and sections were incubated with primary antibodies
Figure 2. Intervention study. A) Effects of combination of ramipril (0.01 mg/kg bw) and telmisartan (0.5 mg/kg bw) or vehicle administered
subcutaneously on the pressor responses to i.v. injected angiotensin I (150 ng/kg bw) or angiotensin II (50 ng/kg bw; n=7). B) Duration of the
pressor responses of selected doses of ramipril (0.01 mg/kg bwt) and telmisartan (0.5 mg/kg bwt) administered subcutaneously induced by
angiotensin I (150 ng/kg bwt) and angiotensin II (50 ng/kg bwt) injected intravenously (n=7 per group); *: p,0.05 vs. ANG II; #: p,0.05 vs. ANG I.
doi:10.1371/journal.pone.0023646.g002
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1:50 in blocking buffer) at 4uC, overnight. After incubation,
primary antibodies were rinsed from sections three times with
PBS. Cy3-conjugated secondary antibodies (1:100 in 5% donkey
serum in PBS, Chemicon, Schwalbach/Ts, Germany) were added
and allowed to incubate for 1 hour at room temperature. The
secondary antibodies were rinsed three times with PBS, and the
sections were treated with 10 ng/ml DAPI for 15 min at room
temperature. After washing for three times with PBS, coverslips
were mounted on slides with mounting medium (Dako Cytoma-
tion, Hamburg, Germany). A Leica DM IRE2 microscope (Leica
Microsystems, Wetzler, Germany) was used to generate the
images. The counting area was determined by comparing HE-
stained section and MRI sections of all animals of this experiment
to choose an area (approximately 1 mm
2 for the Nissl staining and
0.4 mm
2 for the immunostaining) that was part of the penumbra
in all animals. In this experiment, this area was in a periventricular
location. In addition, the corresponding area in the contralateral
hemisphere was investigated. Cells were counted by a blinded
investigator (Figure 4B–E).
Figure 3. Intervention study. A) Effect of 5 day pretreatment with telmisartan (0.5 mg/kg bwt), ramipril (0.02 mg/kg bwt and 0.2 mg/kg bwt) and
their combination (T 0.5 mg/kg bwt, R 0.02 mg/kg bwt) administered subcutaneously on mean arterial blood pressure (mmHg) before, during and
after MCAO. Baseline (230), initiation of anesthesia (215), start of MCAO (0), 90 min. of occlusion (+90) and 30 min. of reperfusion (+120) (n=7 per
group); *: p,0.05 vs. Vehicle. B) Effects of 5 day pretreatment with ramipril, telmisartan and their combination administered subcutaneously at
established doses on body weight gain 48 h after MCAO. Columns from the left: sham, vehicle, telmisartan 0.5 mg/kg (T 0.5), ramipril 0.02 mg/kg (R
0.02), ramipril 0.2 mg/kg (R 0.2) and combination of telmisartan 0.5 mg/kg and ramipril 0.02 mg/kg (T+R 0.5/0.02), n=7 per group. *p,0.05 vs.
vehicle C) Effect of 5 day pretreatment with ramipril, telmisartan and their combination on infarct volume. Columns from the left: vehicle, telmisartan
0.5 mg/kg (T 0.5), ramipril 0.02 mg/kg (R 0.02), ramipril 0.2 mg/kg (R 0.2) and combination of telmisartan 0.5 mg/kg and ramipril 0.02 mg/kg (T+R 0.5/
0.02), n=7 per group. *p,0.05 vs. stroke/vehicle D) Effect of 5 day pretreatment with ramipril, telmisartan and their combination on neurological
deficit score 24 h (bright bars) or 48 h (dark bars) after MCAO. Columns from the left: sham, vehicle, telmisartan 0.5 mg/kg (T 0.5), ramipril 0.02 mg/kg
(R 0.02), ramipril 0.2 mg/kg (R 0.2) and combination of telmisartan 0.5 mg/kg and ramipril 0.02 mg/kg (T+R 0.5/0.02), n=7 per group. *p,0.05 vs.
sham; #: p,0.05 vs. vehicle.
doi:10.1371/journal.pone.0023646.g003
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All data were analysed using SPSS 16.0 for Windows and
presented as arithmetic mean 6 standard error of the mean
(SEM).
Analysis of variance by ANOVA-analysis followed post hoc tests
(Scheffe’- or tukey-test). Differences between groups were
compared by the Wilcoxon rank sum test for independent and
the Wilcoxon signed rank sum test for dependant samples.
Survival was analyzed using Kaplan Meier analysis followed by
log-rank test. Differences between two groups of interest were
analyzed using the Mann-Whitney-U test. Results were considered
significantly different at a value of p,0.05.
Results
Stroke prevention in SHR-SP
Systolic blood pressure in SHR-SP. Figure 1A shows
systolic blood pressure (SBP) during treatment. SBP was
comparable in all groups at the beginning of salt loading. The
development of hypertension was prevented in rats treated with
telmisartan, ramipril and their respective combination.
Course of treatment in SHR-SP. Figure 1A shows the
course of treatment to achieve equal SBP between treatment
groups (150 mmHg) during experiment. With the beginning of the
high salt diet, SHR-SP were randomly assigned to four different
treatment groups: group 1 served as control (untreated; n=24),
group 2 treated with the angiotensin AT1 receptor blocker
telmisartan in the drinking water (initial dose T; 1.23 mg/kg bwt
has to be raised up to 2.31 mg/kg bwt at week 6 and to 3.62 mg/
kg bwt at the end of the study; n=27), group 3 treated with the
ACE-inhibitor ramipril in drinking water (initial dose R; 1.06 mg/
kg bwt has to be raised up to 4.9 mg/kg bwt within week 6 and to
12.87 mg/kg bwt at the end of the study; n=27), and group 4 was
treated with a combination of telmisartan and ramipril in the
drinking water (initial dose T; 0.25 mg/kg bwt plus R, 0.25 mg/kg
bwt; has to be raised up to 0.57 mg/kg bwt each within week 6
and to 0.71 mg/kg bwt each at study end; n=26). The dose of
ramipril had to be increased considerably more to keep blood
pressure at 150 mmHg than the dose of telmisartan. The
respective doses of T and R in combination therapy were
relatively low and ineffective as monotherapy.
Neurological score of SHR-SP. Figure 1B shows the
development of the neurological deficits over time and indicates
the number of animals remaining in each group at the
corresponding time point. Neurological scores were comparable
in all groups at the beginning of the protocol. The development of
neurological deficits was decelerated in rats treated with
telmisartan, ramipril or their combination. At 4 weeks, vehicle-
treated animals began to develop neurological signs associated
with stroke: piloerection, jumping, aggression, prostration, loss of
body symmetry and convulsions. Rats treated with telmisartan,
ramipril or their combination did not display such neurological
signs until the end of the study.
Survival rate in SHR-SP. Survival rates of animals are
summarized in Figure 1C. Fifty percent of the animals in the
vehicle-treated group died within 13 weeks of salt loading.
Telmisartan, ramipril and combination treatment equally
improved survival: within the 13 week duration of the study, all
animals in the treated groups survived.
Stroke verification in SHR-SP. The brains of dead SHR-SP
rats and, after finishing the experiment, the brains of survived
animals were analysed by MRI. All dead SHR-SP animals had
suffered from stroke, and the survived animals showed no signs of
oedema, ischemic or haemorrhagic lesions. See representative
pictures Figure 1D.
Acute intervention study in normotensive rats
Mean arterial blood pressure during MCAO. Blood
pressure was monitored before MCAO in conscious rats, and
during and after MCAO/reperfusion under anaesthesia. Mean
arterial blood pressure remained unchanged and not different
from vehicle-treated controls under the established pre-treatment
doses of telmisartan and ramipril (low dose) or their combination.
In contrast, pre-treatment with ramipril at 0.2 mg/kg bwt (high
dose) significantly reduced mean arterial blood pressure before,
during and after MCAO (Figure 3A).
Blood parameters. Oxygen, carbon dioxide, pH, glucose,
hematocrit, sodium, potassium showed no significant differences
between groups during MCAO (Table S1).
Cerebral blood flow. During MCAO, all animals showed a
significant reduction in CBF in comparison to baseline conditions.
After withdrawal of the occluding filament, ipsilateral blood flow
was restored to approximately 90% of baseline levels. Reductions
in CBF during MCAO and during reperfusion were identical in
vehicle- and drug-treated groups (Figure S3B).
Body weight. After stroke, body weight decreased
significantly in the vehicle-treated group in comparison to sham
operated animals. In the telmisartan and combination pre-treated
groups, but not in the ramipril-pre-treated group, body weight was
not reduced and remained in the range of the sham operated
animals (Figure 3B).
Infarct volume. Cerebral ischemic areas were visualized by
the MRI technique and normalized to body weight. On day 2
after MCAO, the size of ischemic lesions was 150 mm
3/100 g
bwt. on average in vehicle pre-treated animals with MCAO.
Telmisartan- and combination pre-treatment, but not ramipril
Figure 4. Intervention study. A) Typical MRI section showing infracted region (white area) from a Wistar rat 48 h after MCAO, the squares
mentioned the counting area of the paraventricular penumbra in the ipsilateral and the correspondent area in the contralateral site. Representative
pictures of Nissl staining of sham, vehicle, telmisartan 0.5 mg/kg (T 0.5), ramipril 0.02 mg/kg (R 0.02), ramipril 0.2 mg/kg (R 0.2) and combination of
telmisartan 0.5 mg/kg and ramipril 0.02 mg/kg (T+R 0.5/0.02). B) Number of Nissl positive, viable neurons per mm
2 in the periventricular penumbra
and the correspondent contralateral site 48 h after MCAO. Columns from the left: sham, vehicle, telmisartan 0.5 mg/kg (T 0.5), ramipril 0.02 mg/kg (R
0.02), ramipril 0.2 mg/kg (R 0.2) and combination of telmisartan 0.5 mg/kg and ramipril 0.02 mg/kg (T+R 0.5/0.02). *: p,0.05 vs. sham; #: p,0.05 vs.
vehicle C) Relative number of IL-6 positive cells (% of all cells) in the periventricular penumbra and the correspondent contralateral site 48 h after
MCAO. Columns from the left: sham, vehicle, telmisartan 0.5 mg/kg (T 0.5), ramipril 0.02 mg/kg (R 0.02), ramipril 0.2 mg/kg (R 0.2) and combination of
telmisartan 0.5 mg/kg and ramipril 0.02 mg/kg (T+R 0.5/0.02), counting area 0.4 mm
2.* p,0.05 vs. sham D) Relative number of TNF-alpha positive
cells (% of all cells) in the periventricular penumbra and the correspondent contralateral site 48 h after MCAO. Columns from the left: sham, vehicle,
telmisartan 0.5 mg/kg (T 0.5), ramipril 0.02 mg/kg (R 0.02), ramipril 0.2 mg/kg (R 0.2) and combination of telmisartan 0.5 mg/kg and ramipril 0.02 mg/
kg (T+R 0.5/0.02), counting area 0.4 mm
2.* p,0.05 vs. sham; #p,0.05 vs. vehicle E) Relative number of TrkB positive cells (% of all cells) in the
periventricular penumbra and the correspondent contralateral site 48 h after MCAO. Columns from the left: sham, vehicle, telmisartan 0.5 mg/kg (T
0.5), ramipril 0.02 mg/kg (R 0.02), ramipril 0.2 mg/kg (R 0.2) and combination of telmisartan 0.5 mg/kg and ramipril 0.02 mg/kg (T+R 0.5/0.02),
counting area 0.4 mm
2.* p,0.05 vs. sham; #p,0.05 vs. vehicle.
doi:10.1371/journal.pone.0023646.g004
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ischemic area (Figure 3C).
Neurological deficits. In all stroke groups, a significant
reduction in the Garcia score was recorded 24 h and 48 h after
MCAO compared to sham operated animals (Figure 3D).
Neurological outcome was significantly improved in the
telmisartan- and combination-treated group after 24 h as well as
48 h after MCAO. In the ramipril-treated groups the
improvement did not reach statistical significance (Figure 3D).
Mortality. In accordance with the literature [21–23],
mortality rate within the first 24 h after MCAO was between
28% and 30% in all stroke groups.
Neuronal cell loss. For histological assessment of neuronal
damage in the periventricular penumbra, Nissl staining was
performed 48 h after MCAO. In injured neurons, the Nissl
substance breaks apart. Compared with sham operation the
number of Nissl positive cells was markedly reduced in the
ipsilateral penumbra after MCAO (p,0.05), as shown in
Figure 4A. Neuronal loss of the ischemic periventricular
penumbra was significantly improved in telmisartan- and
combination- but not in ramipril pre-treated groups (p,0.05).
The corresponding contralateral brain region showed a significant
reduction of neuronal cells in stroke-vehicle and ramipril treated
groups in comparison to sham operated animals (p,0.05)
(Figure 4B).
IL-6 and TNF-a by Immunohistochemistry. The
proinflammatory cytokines, IL-6 and TNF-a, were significantly
increased 48 h after MCAO in comparison to sham operated
animals.
In both telmisartan- and combination pre-treated groups,
protein levels of TNF-a in the ipsilateral penumbra were
significantly decreased in comparison to the stroke- vehicle group,
whereas IL-6 remained unchanged in all pre-treatment groups.
The expression of TNF-a and IL-6 in the corresponding
contralateral brain region was not different from the one in sham
operated animals (Figure 4C–D)
TrkB by Immunohistochemistry. The BDNF receptor,
TrkB, was significantly down-regulated in the ipsilateral penumbra
48 h after MCAO in the vehicle-treated group in comparison to
sham operated animals. Pre-treatment with telmisartan and the
combination increased, on protein level, the expression of BDNF
receptor TrkB in comparison to stroke-vehicle group. The
expression of receptor TrkB in the corresponding contralateral
brain region was not different from the one in sham operated
animals (Figure 4E).
Discussion
Stroke is one of the leading causes of death and invalidity in the
modern world [24]. Consequently, prevention and treatment of
stroke have become major issues in experimental and clinical
research. Compared to other antihypertensive drugs, angiotensin
AT1-receptor blockers (ARBs) have been demonstrated to be
effective in primary and secondary stroke prevention in several
clinical studies [2–6,25] even when blood-pressure reduction was
similar between different study arms.
In contrast, in The Profess trial on secondary stroke, AT1-
receptor blockade did not confer additional benefit when
compared to other stroke therapies. However, interpretation of
these findings is limited by to the short observation period [26].
The ONTARGET trial compared the efficacy of the angioten-
sin receptor antagonist, telmisartan, the angiotensin-converting
enzyme inhibitor, ramipril, and their combination in reducing
cardio- and cerebrovascular risk [6]. The study population
included patients with or without hypertension, with coronary
artery disease, stroke, peripheral vascular disease or diabetes with
end-organ damage but excluded patients with congestive heart
failure. Telmisartan was not inferior to ramipril with respect to the
primary endpoint including stroke incidence, and the combination
of the two drugs was not superior to each one alone [6].
Concerning stroke prevention, the present results in salt-fed
stroke-prone SHR are in line with those of ONTARGET. With
doses adjusted to achieve equal antihypertensive actions, telmi-
sartan, ramipril or their combination all prevented stroke
incidence and stroke-related neurological deficits during the 13
weeks of observation, while untreated hypertensive controls had a
mortality of 50% at the end and experienced stroke-related
neurological deficits during the course of the study. Like in the
ONTARGET trial, it thus appears that in hypertensive individ-
uals, the blood pressure lowering drug actions determine stroke
incidence with no difference between principles of RAS inhibition.
Interestingly, during the course of treatment, the dose of
ramipril had to be increased considerably more than the
corresponding dose of telmisartan to keep blood pressure at
150 mmHg, and the dose of each compound in combination
therapy was much lower than the respective monotherapy doses.
However, stroke incidence, as much as it is part of the combined
endpoint in many cardiovascular drug trials, constitutes a
relatively crude measure of drug-induced brain protection since
it is mainly related to the vascular, but not to the neuronal part of
the stroke issue. The latter also includes potential neuroprotective
drug effects limiting stroke extension and reducing post-ischemic
neuronal damage.
In this regard, a number of animal studies have suggested that
the beneficial effects of ARBs in stroke include a blood pressure–
independent element of neuroprotection, and some of the
underlying molecular mechanisms have already been described
[14–18,26–29]. With respect to the ACE inhibitors, the experi-
mental and clinical literature presents rather equivocal data on
blood pressure related- or unrelated effects in stroke [1,11,20,30].
In the second part of the present study, we therefore compared
potential blood pressure-independent neuroprotective effects of
systemic pre-treatment with telmisartan, ramipril and their
combination after focal brain ischemia induced by MCAO with
reperfusion in normotensive rats. General criteria of comparative
dose definition were equi-potency with respect to persistent
blockade of the peripheral RAS in vivo (inhibition of the pressor
responses to intravenous Ang I and AngII, respectively) and
absence of blood pressure lowering effects before, during and after
focal brain ischemia.
Given these experimental conditions, pre-treatment with
telmisartan alone and with the combination of telmisartan and
ramipril proved to be more effective than ramipril in reducing
stroke volume, loss of body weight and neurological deficits.
Combination treatment with telmisartan plus ramipril seems to be
not superior to telmisartan alone.
These findings are in line with those of a previous experimental
head-to-head comparison involving candesartan and ramipril [20]
and with most of the animal studies on potential neuroprotective
effects of RAS inhibitors [14–18,20,27–29]. Since cerebral blood
flow was reduced during MCAO to the same extent with no
differences between vehicle-treatment and drugs, mechanisms
other then those merely related to brain perfusion have to be
responsible for differences in neuroprotection between ARBs and
ACE inhibitors.
One simple explanation for our findings could be that ARBs in
general, and telmisartan or candesartan in particular [9,31], have
a higher propensity to cross the blood-brain barrier (BBB) than
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RAS, i.e. inhibit the actions of non-vascular AT1 receptors and
stimulate the actions of unopposed AT2 receptors inside the BBB
[9]. Indeed, it has been demonstrated that AT2 receptors inside
the brain contributes to the neuroprotective effects (reduced infarct
volume and neurological deficits, improved neuronal survival) of
central AT1 receptor blockade after MCAO [18], which is also
underlined by the severe outcome after MCAO in AT2 receptor
KO mice [29] and smaller lesion area and much larger penumbra
in AT1 receptor KO mice [28]. Under this assumption, combined
treatment with telmisartan and ramipril would reflect the central
effects of telmisartan but afford no further benefits by ACE
inhibition beyond AT1 receptor blockade.
Further mechanisms of neuroprotection that may be related to
central AT1 receptor blockade include the neurotrophin receptor
TrkB which showed an enhanced expression under telmisartan
and combination therapy in the penumbra of ischemic brain
tissue. Analyzing BDNF- and TrkB knockout mice, this neurotro-
phin system has been identified to be essential for the development
and survival of several distinct neuronal populations in vitro and
also in vivo [32–34]. We observed an exclusive increase of the TrkB
protein in the telmisartan- and combination group compared to
the other groups with brain ischemia. This finding, reflecting an
intensified interaction of BDNF with its specific receptor, TrkB,
points to a local, molecular mechanism of neuroprotective actions
which may have contributed to the reduced neuronal loss in the
ischemic penumbra under telmisartan- and combination treat-
ment as observed in the present study.
Conclusion
In salt-fed SHR-SP equi-antihypertensive treatment with
telmisartan, ramipril or their combination completely prevented
neurological deficits and stroke occurrence pointing to blood
pressure reduction as the leading mechanism in stroke prevention.
Conversely, in acute stroke intervention in normotensive rats, sub-
antihypertensive pre-treatment with telmisartan and combination
treatment was significantly more effective than ramipril alone in
terms of neuroprotection. The combination of telmisartan and
ramipril seems to be not superior to telmisartan alone in this
experimental setting.
Supporting Information
Figure S1 Study design. A) Prevention study Baseline
measurements were performed at the age of 9 weeks as described
in Material and Methods. Subsequently, all rats were switched to a
high salt diet and randomly assigned to four different treatment
groups. The initial drug doses are indicated. Individual drug doses
were selected on the basis of achieving equal blood pressure
(150 mmHg) throughout the protocol. Several parameters were
estimated in various time-points as indicated in the figure. B)
Intervention study In a pilot study, the appropriate treatment
doses of the drugs were determine as described in Material and
Methods. Based on the dose finding, animals were randomly
allocated to five different treatment groups. Several parameters
were estimated in various time-points as indicated in the figure.
(TIF)
Figure S2 Pilot study. A) Effects of different doses of
telmisartan or vehicle administered subcutaneously on the pressor
responses to intravenously injected angiotensin II (50 ng/kg bw
n=7 per group). B) Effects of different doses of ramipril or vehicle
administered subcutaneously on the pressor responses to intrave-
nously injected angiotensin I (150 ng/kg bw; n=7).
(TIF)
Figure S3 Intervention study. A) Magnetic resonance
angiography of the rat brain from a ventral view before MCAO,
during occlusion and after reperfusion on cerebral perfusion. On
the left: middle cerebral artery before cerebral ischemia was
induced; in the middle: during occlusion is the MCA in the circle
not visible; on the right: the apparent MCA after reperfusion. B)
Changes in the rCBF in the zone of ischemia before, during and
after occlusion of the middle cerebral artery for 90 minutes and
during the reperfusion period in rats treated subcutaneously with
vehicle (white bars; n=12), or telmisartan (light grey bars; n=13)
or ramipril (grey bars; n=11) or combination of telmisartan and
ramipril (black bars; n=8) on 5 consecutive days before the
induction of ischemia. rCBF values (mean 6SD) are expressed as
the percentage of baseline values recorded before occlusion of the
middle cerebral artery. In all groups the reduction of rCBF during
occlusion was significant reduced *p,0.05.
(TIF)
Table S1 Arterial blood oxygen, carbon dioxide, pH values,
glucose, haematocrite, sodium and potassium concentration before
middle cerebral artery occlusion in rats treated subcutaneously
with vehicle (V), telmisartan (T=0.5 mg/kg), or ramipril
(R1=0.01 mg/kg bw; R2=0.1 mg/kg bw) or combination
telmisartan and ramipril (T=0.5 mg/kg bw and R1=0.01 mg/
kg bw).
(TIF)
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